New hope for rare blood cancer patients who failed standard therapies
NCT ID NCT04262141
First seen Jan 09, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This study tests an experimental drug called IMG-7289 in people with two rare blood cancers—essential thrombocythemia (ET) and polycythemia vera (PV)—whose disease did not get better with or could not tolerate standard treatments. The goal is to see if the drug can help control blood cell counts and reduce symptoms. The study is in Phase 2 and involves 4 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Miami
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.